Diabetic Foot Ulcers Pipeline Review 2021

A diabetic foot ulcer is a wound or open sore occurring in about 15 percent of patients suffering from diabetes and is mainly located on the bottom of the foot. Among the patients infected with foot ulcer, 6 percent will be hospitalized due to other ulcer-related complication or infection. Diabetes is the important cause of non-traumatic lower extremity amputations in the U.S., and around 14-24 percent of patients who develop a foot ulcer with diabetes will require an amputation. Foot ulceration leads 85 percent of diabetes-associated amputations.

However, research has stated that development of a foot ulcer is avoidable.  African Americans, Native Americans, Hispanics, and older men are more likely to develop ulcers. Individuals who use insulin has higher risk of developing a foot ulcer along with patients with diabetes-associated eye, kidney, and heart disease.

The number of pharmaceutical companies are involved actively in the development of diabetic foot ulcer therapeutics. For instance, in June 2018, Remedor Biomed Ltd. finalized phase II trials of a hydrogel containing erythropoietin to treat diabetic foot ulcer.  Further, Charsire Biotechnology Corp., in collaboration with ASKLEP Inc., is leading phase II studies to estimate the safety and efficacy of CSTC1 in patients with diabetic foot ulcer.

Approximately 70% of pipeline drugs for diabetic foot ulcers are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent diabetic foot ulcers.

Report Description

The report on Diabetic Foot Ulcers- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Diabetic Foot Ulcers. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Diabetic Foot Ulcers (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline